Immunotherapy and the Journey of a Prostate Cancer Patient [transcript] [audio]
Key Takeaways
- Key Insight: Guest: Andrew Hilew Presenter: Neal Howard Guests Bio: Andrew Hilew, a practicing lawyer, was shocked when he was diagnosed with prostate cancer in 2009.
- Clinical Perspective: Another check of his PSA levels years later showed that his disease had progressed.
- Why It Matters: This discussion provides healthcare professionals with actionable insights relevant to clinical practice and patient care.
- Key Point: Listen to the full episode for detailed discussion and professional insights on this important healthcare topic.
- Key Point: Listen to the full episode for detailed discussion and professional insights on this important healthcare topic.
Guest: Andrew Hilew
Presenter: Neal Howard
Guests Bio: Andrew Hilew, a practicing lawyer, was shocked when he was diagnosed with prostate cancer in 2009. Another check of his PSA levels years later showed that his disease had progressed. So when his urologist recommended tackling his cancer with a new form of treatment for certain patients with advanced prostate cancer called immunotherapy, he was eager to try it. Today, Andrew’s PSA is down from 88 to 2.1. While he continues to undergo treatment for his disease, he still practices law and spends time golfing. Andrew is sharing his story in the hopes of encouraging men – and their loved ones – to be proactive about early detection of prostate cancer, and get educated on testing and advances in treatment.
Segment overview: Andrew Hilew, 71 years old, a husband and father of 5 from Michigan, discusses his journey with his advanced prostate cancer diagnosis and immunotherapy treatment.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
